Compare Genuine Parts Company (GPC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Sanofi SA — how do they compare? Genuine Parts Company trades at $127.27 (market cap $17.67B), while Sanofi SA trades at $40.19 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 5.4× Genuine Parts Company's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Sanofi SA for 94 Days on average.
| GPC | SNY | |
|---|---|---|
Market Cap | $17.67B | $95.18B |
Volume | 1,079,458 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $52.34 |
52-Week Low | $92.47 | $39.51 |
Typical Hold Time | 75 Days | 94 Days |
Enterprise Value | $23.76B | $114.48B |
Dividend Yield | 3.32% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.
The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
